Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-14

Clinical Trial Update: Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating safety, tolerability, and efficacy of aflibercept for neovascular age-related macular degeneration has completed with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aflibercept (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Neovascular (Wet) Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2023-08-14